$0.21
(Market cap
$193 Mln
Revenue (TTM)
$7 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-9.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2
-
Face value
--
-
Shares outstanding
38,546,600
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vaccitech (VACC)
| 49.8 | 19.3 | 11.4 | 46.7 | -- | -- | -- |
|
BSE Sensex*
| -10.2 | -0.9 | -7.6 | -7.0 | 7.1 | 8.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Vaccitech (VACC)
| 49.8 | -78.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vaccitech (VACC)
|
3.5 | 192.7 | 7.3 | -77.3 | -1,200.9 | -36 | -- | 0.4 |
| 77.0 | 10,557.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 17.3 | |
| 76.1 | 10,446.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 50.1 | 12,605.5 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.4 | |
| 120.0 | 15,772.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 69.5 | 8,103.6 | 1,508.5 | 348.8 | 57.0 | 96.4 | 24 | 36.9 | |
| 301.6 | 8,827.7 | 417.3 | 225.0 | 42.8 | 18.6 | 40 | 6.9 | |
| 519.6 | 11,925.8 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.0 | |
| 424.2 | 12,360.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 27.3 | 20.7 | |
| 352.7 | 9,578.0 | 0.0 | -326.5 | -- | -37.2 | -- | 6.8 |
Shareholding Pattern
View DetailsAbout Vaccitech (VACC)
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic... programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. V Read more
-
CEO & Director
Mr. William J. Enright MBA
-
Chief Medical Officer
Dr. Margaret Marshall M.D.
-
Headquarters
Oxford
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Vaccitech (VACC)
What is the current share price of Vaccitech plc (VACC) Today?
The share price of Vaccitech plc (VACC) is $3.52 (NASDAQ) as of 26-Dec-2023 09:30 EDT. Vaccitech plc (VACC) has given a return of 46.67% in the last 1 years.
What is the current PB & PE ratio of Vaccitech plc (VACC)?
Since, TTM earnings of Vaccitech plc (VACC) is negative, P/E ratio is not available.
The P/B ratio of Vaccitech plc (VACC) is 0.36 times as on 22-Dec-2023, a 92 discount to its peers’ median range of 4.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
16.43
|
0.36
|
|
2021
|
-7.71
|
1.56
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
16.43
|
0.36
|
What is the 52 Week High and Low of Vaccitech plc (VACC)?
The 52-week high and low of Vaccitech plc (VACC) are Rs -- and Rs -- as of 26-May-2026.
What is the market cap of Vaccitech plc (VACC)?
Vaccitech plc (VACC) has a market capitalisation of $ 193 Mln as on 22-Dec-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Vaccitech plc (VACC)?
Before investing in Vaccitech plc (VACC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.